Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 4/20 | 0.53 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | CXCR3 | P49682 | 3/20 | 0.34 |
| ▸ | CYP26A1 | O43174 | 3/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5121910 | 0.85 | HSD11B1 (0.59) | HSD11B1CXCR3 | |
| SCHEMBL5127771 | 0.83 | HSD11B1 (0.51) | HSD11B1ROCK2 | |
| SCHEMBL2999509 | 0.83 | HSD11B1 (0.57) | HSD11B1ROCK2CXCR3 | |
| SCHEMBL5131933 | 0.83 | HSD11B1 (0.46) | HSD11B1 | |
| Hydrochloric Acid SCHEMBL5129245 | 0.82 | HSD11B1 (0.50) | HSD11B1ROCK2 | |
| SCHEMBL2991762 | 0.82 | HSD11B1 (0.50) | HSD11B1ROCK2CYP26A1ESR2 | |
| SCHEMBL5129287 | 0.81 | HSD11B1 (0.44) | HSD11B1 | |
| SCHEMBL4524294 | 0.81 | HSD11B1 (0.59) | HSD11B1ROCK2 | |
| Hydrochloric Acid SCHEMBL5125467 | 0.80 | HSD11B1 (0.43) | HSD11B1 | |
| SCHEMBL4511122 | 0.80 | HSD11B1 (0.63) | HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100184764-A1 | CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY (US) | 2010-07-22 | — | — | US | disclosed |
| US-20100184764-A1 | CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY (US) | 2010-07-22 | — | — | US | disclosed |
| US-7713979-B2 | Cycloalkyl lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 | ELI LILLY AND COMPANY (US) | 2010-05-11 | — | — | US | disclosed |
| US-7713979-B2 | Cycloalkyl lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 | ELI LILLY AND COMPANY (US) | 2010-05-11 | — | — | US | disclosed |
| US-20080275043-A1 | Cycloalkyl Lactam Derivatives as Inhibitors of 11-Beta-Hydroxysteroid Dehydrogenase 1 | ELI LILLY AND COMPANY | 2008-11-06 | — | — | US | disclosed |
| US-20080275043-A1 | Cycloalkyl Lactam Derivatives as Inhibitors of 11-Beta-Hydroxysteroid Dehydrogenase 1 | ELI LILLY AND COMPANY | 2008-11-06 | — | — | US | disclosed |
| EP-1807072-A1 | CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY (US) | 2007-07-18 | — | — | EP | disclosed |
| WO-2006049952-A1 | CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY (US) | 2006-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275043-A1 | Cycloalkyl Lactam Derivatives as Inhibitors of 11-Beta-Hydroxysteroid Dehydrogenase 1 | HSD11B1, HSDL2, HSD17B1 | HSD11B1 1/4885ROCK2 3649/4885CXCR3 2578/4885 |
| US-20100184764-A1 | CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | HSD11B1, HSD17B1, HSD3B1 | HSD11B1 1/4885ROCK2 3201/4885CXCR3 1332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.